Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
2B
Biotechnology
Next Earning date - 05 Nov 2024
2B
Biotechnology
Next Earning date - 05 Nov 2024
Relative Strenght
73Volume Buzz
10%Earning Acce
YesDist 52w H.
51%